Drug Trial Radar · NCT06600789
A Modular Phase 1/2 Study With CT7439 in Participants With Solid Malignancies
Last checked: Nov 19, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Aug 16, 2024
Primary completion
Mar 14, 2027
Study completion Mar 14, 2027
Sponsor
- Lead sponsor
- Carrick Therapeutics LimitedIndustry
- Sponsor type
- Industry
- First posted
- Sep 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This modular, multi-part, multi-arm, Phase 1/2, FIH study allows the evaluation of the safety and tolerability of CT7439, dosed as a monotherapy and in combination with anticancer treatment in participants with solid malignancies.
Conditions
- Solid Malignancies
Interventions
CT7439 Capsules (0.5 mg, 1mg, 3mg, 10mg, 15mg, 20mg)Drug
CT7439 capsules administered by mouth once a day as monotherapy with a single starting dose of 1mg in Cohort 1 on Cycle 0 Day 1, followed by a minimum 48 hours treatment -free period before continuous daily dosing in cycles of 28 days (Cycle1 onwards) until DLT or disease progression is observed. Different dosing schedules might be explored in cohorts (BID or intermitting dosing).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of treatment emergent adverse events will be assessed as per CTCAE v5.0.Time frame: From first dosing at Cycle 0 to until 30 days after the last dose at Cycle 6. Each cycle is 28 days
- Incidence and severity of treatment emergent Laboratory Abnormalities will be assessed as per CTCAE v5.0.Time frame: From first dosing at Cycle 0 to until 30 days after the last dose at Cycle 6. Each cycle is 28 days.
- Change from Baseline in Eastern Cooperative Oncology Group Cooperative Oncology Group (ECOG) Performance scale.Time frame: Screening, Cycle 0 - Days 1 and Day 2; Cycle 1 - Days 1,8,15; Cycle 2 Day 1 - Cycle 6 Day 1 (each cycle 28 days); End of Treatment (within 3 days after last CT7439 dose) and End of Study (30 +/-7 days after the last CT7439 dose)
- Systolic Blood Pressure as determined by blood pressure changes from baseline in systolic blood pressure (measured in mmHg)Time frame: Screening, Cycle 0 - Days 1 and Day 2; Cycle 1 - Days 1,8,15; Cycle 2 Day 1 - Cycle 6 Day 1 (each cycle 28 days); End of Treatment (within 3 days after last CT7439 dose) and End of Study (30 +/-7 days after the last CT7439 dose)
- Diastolic Blood Pressure as determined by blood pressure changes from baseline in diastolic blood pressure (measured in mmHg)Time frame: Screening, Cycle 0 - Days 1 and Day 2; Cycle 1 - Days 1,8,15; Cycle 2 Day 1 - Cycle 6 Day 1 (each cycle 28 days); End of Treatment (within 3 days after last CT7439 dose) and End of Study (30 +/-7 days after the last CT7439 dose)
- Heart Rate as determined by heart rate changes from baseline in beats per minuteTime frame: Screening, Cycle 0 - Days 1 and Day 2; Cycle 1 - Days 1,8,15; Cycle 2 Day 1 - Cycle 6 Day 1 (each cycle 28 days); End of Treatment (within 3 days after last CT7439 dose) and End of Study (30 +/-7 days after the last CT7439 dose)
- Body Temperature. as determined by body temperature changes from baseline in Celsius or FahrenheitTime frame: Screening, Cycle 0 - Days 1 and Day 2; Cycle 1 - Days 1,8,15; Cycle 2 Day 1 - Cycle 6 Day 1 (each cycle 28 days) End of Treatment (within 3 days after last CT7439 dose) and End of Study (30 +/-7 days after the last CT7439 dose)
- Respiratory Rate as determined by respiratory rate changes from baseline in breaths per minuteTime frame: Screening, Cycle 0 - Days 1 and Day 2; Cycle 1 - Days 1,8,15; Cycle 2 Day 1 - Cycle 6 Day 1 (each cycle 28 days); End of Treatment (within 3 days after last CT7439 dose) and End of Study (30 +/-7 days after the last CT7439 dose)
- Oxygen Saturation as determined by changes from baseline in %Time frame: Screening, Cycle 0 - Days 1 and Day 2; Cycle 1 - Days 1,8,15; Cycle 2 Day 1 - Cycle 6 Day 1 (each cycle 28 days); End of Treatment (within 3 days after last CT7439 dose) and End of Study (30 +/-7 days after the last CT7439 dose)
- Change from Baseline in 12-lead Electrocardiogram (ECG): Heart RateTime frame: From baseline to end of Cycle 6 (each cycle is 28 days); End of Treatment (within 3 days after last CT7439 dose) and End of Study (30 +/-7 days after the last CT7439 dose)
- Change from Baseline in 12-lead Electrocardiogram (ECG): PR intervalTime frame: From baseline to end of Cycle 6 (each cycle is 28 days); End of Treatment (within 3 days after last CT7439 dose) and End of Study (30 +/-7 days after the last CT7439 dose)
- Change from Baseline in 12-lead Electrocardiogram (ECG): QRS complexTime frame: From baseline to end of Cycle 6 (each cycle is 28 days); End of Treatment (within 3 days after last CT7439 dose) and End of Study (30 +/-7 days after the last CT7439 dose)
- Change from Baseline in 12-lead Electrocardiogram (ECG): QT intervalsTime frame: From baseline to end of Cycle 6 (each cycle is 28 days); End of Treatment (within 3 days after last CT7439 dose) and End of Study (30 +/-7 days after the last CT7439 dose)
- Change from Baseline in 12-lead Electrocardiogram (ECG): QTcF intervals (QT Interval Corrected by the Fridericia Formula)Time frame: From baseline to end of Cycle 6 (each cycle is 28 days); End of Treatment (within 3 days after last CT7439 dose) and End of Study (30 +/-7 days after the last CT7439 dose)
- Module 1 Part A additional primary outcome measures: Maximum tolerated dose (MTD) determinationTime frame: Up to 28 days after the first dose of CT7439
Locations
6 sites in 2 countries. Site status is shown where the registry gives one.
Research site 03
Dallas, Texas · Recruiting
Research site 01
San Antonio, Texas · Recruiting
Research site 02
Fairfax, Virginia · Recruiting
Research site 05
Manchester, United Kingdom · Recruiting
Research site 04
Oxford, United Kingdom · Recruiting
Research site 06
Sutton, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.